Posted by Michael Wonder on 27 May 2026
Autobahn Therapeutics announces US FDA fast track designation for elunetirom, a CNS directed thyroid hormone receptor agonist, for the adjunctive treatment of bipolar depression
26 May 2026 - Autobahn Therapeutics today announced that the US FDA granted fast track designation to elunetirom, the Company’s lead candidate, for the adjunctive treatment of depressive episodes associated with bipolar I or bipolar II disorder in adults.
Elunetirom is an oral, once daily, brain penetrant, CNS thyroid hormone receptor agonist that Autobahn is developing as an adjunctive treatment for bipolar depression and major depressive disorder.
